Aims: Many authors do not recommend hypoglycemic treatment during pregnancy in women affected by monogenic diabetes due to heterozygous glucokinase (GCK) mutations (MODY 2) in case of affected fetus, because maternal hyperglycemia would be necessary to achieve a normal birthweight. We aimed to evaluate differences in birthweight between MODY 2 affected children according to the parent who carried the mutation. Methods: We retrospectively studied 48 MODY 2 affected children, whose mothers did not receive hypoglycemic treatment during pregnancy, divided into two groups according to the presence of the mutation in the mother (group A) or in the father (group B). Data were extracted from the database of the Regional Centre of Pediatric Diabetology of the University of Campania, Naples, collected from 1996 to 2016. We analyzed birthweight and centile birthweight. Results: Percentage of small for gestational age was significantly higher in group B than in group A. We found three large for gestational age in the group that inherited the deficit from the mother, all with the same novel GCK mutation (p.Lys458-Cys461del). Conclusions: We hypothesize that not all MODY 2 affected fetuses need the same levels of hyperglycemia to have an appropriate growth, maybe because different kinds of GCK mutations may result in different phenotypes. Consequently, a “tailored therapy” of maternal hyperglycemia, based on fetal growth frequently monitored through ultrasounds, is essential in MODY 2 pregnancies.

Glucokinase deficit and birthweight. does maternal hyperglycemia always meet fetal needs? / Bitterman, O; Tinto, N; Franzese, A; Iafusco, F; Festa, C; Mozzillo, E; Napoli, A; Iafusco, D. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - 55:12(2018), pp. 1247-1250. [10.1007/s00592-018-1198-8]

Glucokinase deficit and birthweight. does maternal hyperglycemia always meet fetal needs?

Bitterman O;Festa C;Napoli A;
2018

Abstract

Aims: Many authors do not recommend hypoglycemic treatment during pregnancy in women affected by monogenic diabetes due to heterozygous glucokinase (GCK) mutations (MODY 2) in case of affected fetus, because maternal hyperglycemia would be necessary to achieve a normal birthweight. We aimed to evaluate differences in birthweight between MODY 2 affected children according to the parent who carried the mutation. Methods: We retrospectively studied 48 MODY 2 affected children, whose mothers did not receive hypoglycemic treatment during pregnancy, divided into two groups according to the presence of the mutation in the mother (group A) or in the father (group B). Data were extracted from the database of the Regional Centre of Pediatric Diabetology of the University of Campania, Naples, collected from 1996 to 2016. We analyzed birthweight and centile birthweight. Results: Percentage of small for gestational age was significantly higher in group B than in group A. We found three large for gestational age in the group that inherited the deficit from the mother, all with the same novel GCK mutation (p.Lys458-Cys461del). Conclusions: We hypothesize that not all MODY 2 affected fetuses need the same levels of hyperglycemia to have an appropriate growth, maybe because different kinds of GCK mutations may result in different phenotypes. Consequently, a “tailored therapy” of maternal hyperglycemia, based on fetal growth frequently monitored through ultrasounds, is essential in MODY 2 pregnancies.
2018
fetal growth; gestational diabetes; mody; monogenic diabetes; pregnancy; internal medicine; endocrinology, diabetes and metabolism; endocrinology
01 Pubblicazione su rivista::01a Articolo in rivista
Glucokinase deficit and birthweight. does maternal hyperglycemia always meet fetal needs? / Bitterman, O; Tinto, N; Franzese, A; Iafusco, F; Festa, C; Mozzillo, E; Napoli, A; Iafusco, D. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - 55:12(2018), pp. 1247-1250. [10.1007/s00592-018-1198-8]
File allegati a questo prodotto
File Dimensione Formato  
Bitterman_Glucokinase_2018.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 620.7 kB
Formato Adobe PDF
620.7 kB Adobe PDF   Contatta l'autore
Bitterman_Glucokinase_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 602.51 kB
Formato Adobe PDF
602.51 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1173664
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact